慢性淋巴细胞白血病患者接种SARS-CoV-2疫苗后免疫保护的相关因素
本研究全面检测了慢性淋巴细胞白血病(CLL)患者对SARS-CoV-2疫苗的体液和细胞免疫应答。55.2%的CLL患者出现血清学转换,接受治疗的患者转换率和抗体滴度更低;T细胞应答在相当比例患者中可检测到,CD4+和CD8+频率显著增加且独立于血清学状态,BTK或BCL-2抑制剂治疗者CD4+细胞水平更高。疫苗使CD8+细胞偏向高细胞毒性表型,在血清学转换者中更明显。多数患者出现产IFNγ和TNFα的刺突特异性CD4+和CD8+细胞,BTK抑制剂治疗者CD4+细胞产IFNγ和TNFα增加。疫苗诱导Th1极化,逆转多数患者的Th2 CLL T细胞特征,未治疗和BTK抑制剂治疗者IL-4产生降低。在540例患者队列中,此类强T细胞应答可能对预防住院和死亡发挥了显著保护作用。
要点
- CLL患者疫苗血清学转换率为55.2%,接受治疗者转换率和抗体滴度更低。
- T细胞应答在相当比例患者中可检测到,CD4+和CD8+频率显著增加且独立于血清学。
- BTK或BCL-2抑制剂治疗者CD4+细胞水平更高;BTK抑制剂治疗者CD4+细胞产IFNγ和TNFα增加。
核心结论
- CLL患者接种SARS-CoV-2疫苗可诱导T细胞应答,包括CD4+和CD8+频率增加、高细胞毒性CD8+表型、Th1极化及IFNγ和TNFα产生,这些强T细胞应答可能对预防住院和死亡发挥显著保护作用。
- 将T细胞指标与血清阳性率结合可能更准确评估CLL人群免疫,为公共卫生提供重要启示。
研究设计与样本
- 本研究全面检测了慢性淋巴细胞白血病(CLL)患者对SARS-CoV-2疫苗的体液和细胞免疫应答。
- 研究队列包括540例患者。
主要发现
- 55.2%的CLL患者出现血清学转换,接受治疗的患者转换率和抗体滴度更低。
- T细胞应答在相当比例患者中可检测到,CD4+和CD8+频率显著增加且独立于血清学状态,接受BTK或BCL-2抑制剂治疗的患者CD4+细胞水平更高。
- 疫苗使CD8+细胞偏向高细胞毒性表型,在血清学转换患者中更明显。
- 高比例患者出现产IFNγ和TNFα的刺突特异性CD4+和CD8+细胞,接受BTK抑制剂治疗的患者CD4+细胞产IFNγ和TNFα增加。
- 疫苗诱导Th1极化,逆转多数患者的Th2 CLL T细胞特征,未治疗和BTK抑制剂治疗患者IL-4产生降低。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In chronic lymphocytic leukaemia (CLL) the efficacy of SARS-CoV-2 vaccination remains unclear as most studies have focused on humoral responses. Here we comprehensively examined humoral and cellular responses to vaccine in CLL patients. Seroconversion was observed in 55.2% of CLL with lower rate and antibody titres in treated patients. T-cell responses were detected in a significant fraction of patients. CD4+ and CD8+ frequencies were significantly increased independent of serology with higher levels of CD4+ cells in patients under a Bruton tyrosine kinase (BTK) or a B-cell lymphoma 2 (BCL-2) inhibitor. Vaccination skewed CD8+ cells towards a highly cytotoxic phenotype, more pronounced in seroconverted patients. A high proportion of patients showed spike-specific CD4+ and CD8+ cells producing interferon gamma (IFNγ) and tumour necrosis factor alpha (TNFα). Patients under a BTK inhibitor showed increased production of IFNγ and TNFα by CD4+ cells. Vaccination induced a Th1 polarization reverting the Th2 CLL T-cell profile in the majority of patients with lower IL-4 production in untreated and BTK-inhibitor-treated patients. Such robust T-cell responses may have contributed to remarkable protection against hospitalization and death in a cohort of 540 patients. Combining T-cell metrics with seroprevalence may yield a more accurate measure of population immunity in CLL, providing consequential insights for public health.
引用
- Sorcini D, De Falco F, Gargaro M, et al. Immune correlates of protection by vaccine against SARS-CoV-2 in patients with chronic lymphocytic leukaemia. Br J Haematol. 2022. PMID: 36484163. doi:10.1111/bjh.18602
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。